# US 2010/0076051 A1 · Isoindolinone kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0076051 A1
- Document ID: US20100076051A1
- Status: Published application
- Kind: A1
- Application number: 12/625,958
- Filed: 2009-11-25
- Published: 2010-03-25
- Earliest claimed: 2003-06-02
- Assignees: Abbott Laboratories
- Inventors: Michael L. Curtin; Steven K. Davidsen; Robin R. Frey; Howard R. Heyman; James H. Holms; Michael Michaelides; Douglas H. Steinman
- Web page: https://patentgrep.com/patent/US20100076051A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61P 35/04: specific for metastasis
- C07D 209/46: with an oxygen atom in position 1
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

## Claims

### Claim 1

A method for inhibiting a protein kinase in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of formula (I)
or a therapeutically acceptable salt thereof, wherein
R1 is selected from the group consisting of hydrogen and alkyl;
R2 is selected from the group consisting of hydrogen, alkoxy, alkoxyalkoxy, alkyl, carboxyalkoxy, carboxyalkyl, halo, haloalkyl, heterocyclylalkoxy, hydroxy, nitro, and —NRcRd; and
one of R3 and R4 is A-X-R5 and the other is hydrogen; wherein A-X-R5 is drawn with its left end attached to the parent molecular moiety;
R5 is selected from the group consisting of aryl, heteroaryl, and heterocyclyl;
A is selected from the group consisting of aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted with one or two substituents independently selected from the group consisting of alkyl, halo, haloalkoxy, and haloalkyl; and
X is selected from the group consisting of O, NRa, N(Ra)C(S)N(Rb), (CH2)mN(Ra)C(O)N(Rb)(CH2)n, CH2C(O)N(Ra), and N(Ra)C(O), wherein Ra and Rb are independently selected from the group consisting of hydrogen and alkyl, m and n are independently 0 or 1, and wherein each group is drawn with its left end attached to A and its right end attached to R5.

### Claim 2

A method for treating cancer in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of formula (I)
or a therapeutically acceptable salt thereof, wherein
R1 is selected from the group consisting of hydrogen and alkyl;
R2 is selected from the group consisting of hydrogen, alkoxy, alkoxyalkoxy, alkyl, carboxyalkoxy, carboxyalkyl, halo, haloalkyl, heterocyclylalkoxy, hydroxy, nitro, and —NRcRd; and
one of R3 and R4 is A-X-R5 and the other is hydrogen; wherein A-X-R5 is drawn with its left end attached to the parent molecular moiety;
R5 is selected from the group consisting of aryl, heteroaryl, and heterocyclyl;
A is selected from the group consisting of aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted with one or two substituents independently selected from the group consisting of alkyl, halo, haloalkoxy, and haloalkyl; and
X is selected from the group consisting of O, NRa, N(Ra)C(S)N(Rb), (CH2)mN(Ra)C(O)N(Rb)(CH2)n, CH2C(O)N(Ra), and N(Ra)C(O), wherein Ra and Rb are independently selected from the group consisting of hydrogen and alkyl, m and n are independently 0 or 1, and wherein each group is drawn with its left end attached to A and its right end attached to R5.
